Clinical Trial Update: Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 [Phase 2]

View source ↗

Summary

Phase 2 trial assessing biomarker-driven therapy with nivolumab and ipilimumab for metastatic hormone-resistant prostate cancer expressing AR-V7 has completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer, Recurrent Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2022-02-03